[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:nf1-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"NF1 Gene",27,22,[8,16,22,29,35,41,47,54,60,66,72,78,84,90,96,101,107,113,119,125,131,137,142,149,155,162,169],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06411821","Ulixertinib in People With Histiocytic Neoplasms",[12],"Phase 2","RECRUITING","2026-08-26T02:17:05.997056Z","2026-07-05T05:32:16.753306Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07237100","Mirdametinib in Patients With Advanced NF1-mutant Melanoma",[12],"2026-08-26T02:17:41.695983Z","2026-05-05T02:43:29.510066Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06299839","PAS-004 in Patients With Advanced Solid Tumors",[26],"Phase 1","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.322222Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":20,"content_modified":34},"NCT07539441","A Study of Mirdametinib in People With Central Nervous System Tumors",[33],"Phase 1\u002FPhase 2","2026-05-05T02:43:29.284240Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT04923126","SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma",[33],"2026-08-26T02:14:59.425132Z","2026-05-05T02:43:28.957186Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.882922Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT06693284","A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST]",[51],"Early Phase 1","2026-08-26T02:19:02.550788Z","2026-05-05T02:43:27.752468Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06961565","PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas",[26],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:27.513386Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT04750928","Cyclin-Dependent Kinase (CDK)4\u002F6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas",[33],"2026-08-26T02:16:05.813655Z","2026-05-05T02:43:27.316168Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06007924","A Study of Avutometinib and Defactinib in People With Thyroid Cancer",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:27.103317Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06194929","Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",[33],"2026-08-26T02:15:10.362237Z","2026-05-05T02:43:26.716817Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT05849662","A Phase I\u002FII Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia",[33],"2026-08-26T02:15:39.267524Z","2026-05-05T02:43:28.528927Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05009992","Combination Therapy for the Treatment of Diffuse Midline Gliomas",[12],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.301737Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07032727","Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations",[12],"2026-08-26T02:15:38.131683Z","2026-05-05T02:43:28.209956Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":76,"content_modified":100},"NCT06712875","MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas",[33],"2026-04-29T02:57:57.125147Z",{"nct_id":102,"title":103,"phases":104,"status":13,"updated_at":105,"content_modified":106},"NCT07252479","Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations",[26],"2026-08-26T02:16:01.910993Z","2026-06-16T05:54:07.937487Z",{"nct_id":108,"title":109,"phases":110,"status":13,"updated_at":111,"content_modified":112},"NCT05512208","A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib",[12],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:29.586102Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT05039801","IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors",[26],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.070174Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT05941520","Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer",[12],"2026-08-26T02:17:39.048487Z","2026-07-19T19:36:05.126907Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT06195306","Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction",[12],"2026-08-26T02:18:31.164304Z","2026-05-05T02:43:26.724920Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT05111561","Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced\u002FMetastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer",[26],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.906567Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":14,"content_modified":141},"NCT06514898","Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma",[26],"2026-06-14T18:39:22.236841Z",{"nct_id":143,"title":144,"phases":145,"status":146,"updated_at":147,"content_modified":148},"NCT07521657","Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:25.538428Z","2026-05-05T02:43:27.841887Z",{"nct_id":150,"title":151,"phases":152,"status":146,"updated_at":153,"content_modified":154},"NCT07690852","Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care",[],"2026-08-26T02:16:24.970704Z","2026-07-19T19:36:05.153122Z",{"nct_id":156,"title":157,"phases":158,"status":159,"updated_at":160,"content_modified":161},"NCT06300502","Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)",[26],"ENROLLING_BY_INVITATION","2026-08-26T02:16:22.235886Z","2026-06-16T05:54:07.723494Z",{"nct_id":163,"title":164,"phases":165,"status":166,"updated_at":167,"content_modified":168},"NCT06507306","A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[26],"ACTIVE_NOT_RECRUITING","2026-08-03T02:23:21.062956Z","2026-04-29T02:57:57.103001Z",{"nct_id":170,"title":171,"phases":172,"status":166,"updated_at":173,"content_modified":174},"NCT05554328","Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial",[12],"2026-08-03T03:36:04.680662Z","2026-05-05T02:43:27.963217Z"]